Medication-assisted Treatment Market size is poised to reach USD 24.7 Million by the end of 2036, growing at a CAGR of 11.4% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of medication-assisted treatment was USD 13.3 Million. This can be attributed to the rising prevalence of substance use disorder among individuals. According to recent information, around 286 Million people aged 15-64 used drugs worldwide in 2020, a 26 percent increase over the past decade.
In addition, with the advancement in medications and therapies such as the availability of a variety of medications like methadone, naltrexone. There is a continuous improvement in behavioral therapies and pharmacological treatments which is enhancing the efficacy of medication-assisted treatment. Moreover, the development of long-acting formulations and innovative delivery methods is also driving the medication-assisted treatment market growth.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~ 11.4% |
|
Base Year Market Size (2023) |
~ USD 13.3 Million |
|
Forecast Year Market Size (2036) |
~ USD 24.7 Million |
|
Regional Scope |
|
Treatment Type (Drug Type, Counseling & Therapies)
The drug type segment in the medication-assisted treatment market is estimated to gain the largest revenue share of about 56% by 2036. The segment growth can be attributed to the factor that the pharma industry’s innovation in MAT, along with the growing awareness and acceptance of these treatments, further propels the drug-type segment expansion within the market. In addition, the market in the drug type segment is also influenced by the development of medication designed to assist individuals recovering from substance use disorder. According to recent data, substance use disorders cost employer-sponsored health insurance over USD 35 Billion in 2023.
End-User (Hospital, Rehabilitation Clinic, Home Care Setting)
The hospital segment in the medication-assisted treatment market is estimated to gain the largest reevenue share of about 53% in the year 2036. The segment growth can be attributed to the factor that hospitals are integral in providing MAT due to their capacity for specialized care, medical expertise, and resources. In addition, hospitals often offer inpatient MAT programs, providing a controlled and supervised environment for individuals undergoing treatment. This approach allows for intensive medical monitoring and adjustment of medication dosages based on individual needs which stimulate the segment growth.
Our in-depth analysis of the global market includes the following segments:
|
Treatment Type |
|
|
End-User |
|
North American Market Forecast
Medication-assisted Treatment market in the North America region is anticipated to hold the largest share of about 45% by the end of 2036. The regional growth is attributed to the factor that government, healthcare, organizations, and philanthropic entities in the region have allocated increased funding and resources to support MAT initiatives. This financial backing has enabled the expansion of treatment facilities, training programs, and public awareness campaigns. According to the National Institute on Drug Abuse, methadone treatment, including medication and integrated psychosocial & medical support services cost USD 6, 55, 20 per year in the US. In addition, the region has recognized the importance of MAT in treating opioid addiction and regulatory frameworks have been adapted to facilitate the integration of MAT into mainstream healthcare, ensuring better access to these treatments for individuals in need and stimulate the market in the region.
European Market Analysis
The Europe medication-assisted treatment market is estimated to the second largest revenue share of about 30% by the end of 2036. The market’s expansion can be attributed to the multidisciplinary approach adopted by the European healthcare system to deal with substance disorders. MAT is integrated into this approach, combining medications with counseling and psychosocial support to address the complex nature of substance use disorders comprehensively. In addition, Community-based MAT programs have been established in various European regions. For example, a Harm reduction program encompasses interventions and policies that seek to mitigate the health, social, and economic harms of drug use to individuals, communities, and societies. These initiatives focus on providing localized and accessible treatment options, emphasizing the importance of community involvement and support in the recovery process which further stimulate the medication-assisted treatment market in the region.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?